Results 41 to 50 of about 6,458 (228)

Association of Ebtifibatide Administration Timing and TIMI Flow of Infarct Related Artery During Primary PCI

Majalah Kardiologi Indonesia, 2013
Background. Optimal administration timing of Glicoprotein IIb/IIIa inhibitor in STEMI patients undergoing Primary PCI is controversial. Several stud -ies have shown that early administration of eptifibatide, which is given to patients with pain awitan of
Abdul Hakim Alkatiri, Yoga Yuniadi, Dicky A Hanafy, Doni Firman, Sunarya Soerianata   +4 more
doaj   +1 more source

Recreation of the terminal events in physiological integrin activation. [PDF]

, 2010
Increased affinity of integrins for the extracellular matrix (activation) regulates cell adhesion and migration, extracellular matrix assembly, and mechanotransduction.
Bobkov, Andrey A, Ginsberg, Mark H, Hu, Guiqing, McLean, Mark A, Ratnikov, Boris, Sligar, Stephen G, Taylor, Dianne, Taylor, Kenneth A, Ye, Feng   +8 more
core   +3 more sources

Ticagrelor and Eptifibatide Bolus Versus Ticagrelor and Eptifibatide Bolus With 2‐Hour Infusion in High‐Risk Acute Coronary Syndromes Patients Undergoing Early Percutaneous Coronary Intervention

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2017
BackgroundIn patients with non‐ST‐segment elevation acute coronary syndromes, inhibition of platelet aggregation (IPA) with a potent P2Y12 inhibitor, ticagrelor, was inferior to tirofiban infusion at 2 hours, indicating that glycoprotein IIb/IIIa ...
Moazez J. Marian, Oluseun Alli, Firas Al Solaiman, Brigitta C. Brott, Mark Sasse, Tara Leesar, Sumanth D. Prabhu, Massoud A. Leesar   +7 more
doaj   +1 more source

Cryo-EM structures of full-length integrin αIIbβ3 in native lipids

Nature Communications, 2023
Platelet integrin αIIbβ3 is maintained in a bent inactive state (low affinity to physiologic ligand), but can rapidly switch to a ligand-competent (high-affinity) state in response to intracellular signals (“inside-out” activation).
Brian D. Adair, Jian-Ping Xiong, Mark Yeager, M. Amin Arnaout   +3 more
doaj   +1 more source

Integrins as therapeutic targets: lessons and opportunities. [PDF]

, 2010
The integrins are a large family of cell adhesion molecules that are essential for the regulation of cell growth and function. The identification of key roles for integrins in a diverse range of diseases, including cancer, infection, thrombosis and ...
A Artoni, A Carter, A Etzioni, A Kato, A Loughman, A McDowall, A Qu, A Robinson, A Salas, AD Ricart, AJ Ablooglu, AL Muranyi, AM Weljie, AR Reynolds, AW Partridge, B Furie, BG Feagan, BG Petrich, BP Feuston, BS Coller, C Delbaldo, C Kummer, C Kummer, C Leonardi, C Lu, C Ng, C Rosano, C Warnke, C Xie, CH Polman, CJ Avraamides, CL Leonardi, CL Tofteng, CS Tan, CS Yoon, D Chua, D Cox, D Cox, D Larkin, D Potin, DA Calderwood, DA Calderwood, DA Chudakova, DA Reardon, Dermot Cox, DJ White, DP Chew, DR Phillips, DS Dodd, DS Harburger, E Bernard, E Havrdova, E Manevich, E Ruoslahti, EO Major, FC Gushiken, FE Fleming, G Weitz-Schmidt, GA Caputo, GM D'Abaco, GPA Rice, H Jin, H Yin, H Zhang, H-J Lee, I Ahrens, J Bennett, J Kallen, J Kalra, J Lim, J Morova, J Takagi, J Takagi, J Tamkun, JA Askari, JA Nemeth, JC O'Shea, JE Frampton, JE Smith-Garvin, JP Ortonne, JP Xiong, JP Xiong, JR Fitzgerald, JR Fitzgerald, JR Morgan, JW Tilley, K Aylward, K Peter, K Peter, K Welzenbach, K Yao, K Yuki, KB Gordon, KB Reddy, KL Graham, KL Graham, KL Schornberg, KL Wegener, KR Legate, KV Vijayan, L Dubertret, L Steinman, L Xudong, LM Kenny, M Brennan, M Champe, M Egbertson, M Kim, M Lebwohl, M Martchenko, M Moser, M Raab, M Rosenthal, M Shimaoka, M Shimaoka, M Shimaoka, M Shimaoka, MA Arnaout, Marian Brennan, MC Joseph, ME Cianfrocca, MG Murphy, MN Younes, MP Bonaca, MP Brennan, MP Crump, N Laurens, Niamh Moran, NS Nicholson, O Vinogradova, O Vinogradova, P Hersey, P Koistinen, PA Calabresi, PC McDonald, PE Hughes, PL Stewart, QY Liu, R Anders, R Axelsson, R Blue, R Curtin, R Evans, R Gonzalez-Amaro, R Pytela, R Silva, R Stragies, R Stupp, RA Rudick, RH Aster, RJ Davenport, RJ Davenport, RM Scarborough, RO Hynes, RP Dassanayake, S Honda, S Honda, S Kim, S Kim, S Li, S Liu, S Moschos, S O'Neill, S Wattanasin, SH Watterson, SJ Hyduk, SJ Monkley, SJ Moschos, SJ Shattil, SM Keating, SM Weis, SR Barthel, SR Targan, T Dileepan, T Kwok, T Weller, T Xiao, TA Kelly, TA Yednock, TC Sroka, TE O'Toole, TE Spencer, TJ MacDonald, TM Brophy, TR Gadek, UP Naik, VA Umans, W Humphrey, W Jia, W Neidhart, W Wang, W Yang, X Sewald, Y Aga, Y Funahashi, Y Gong, Y Li, Y Wang, YF Li, YQ Ma   +199 more
core   +1 more source

Newer agents in antiplatelet therapy: a review. [PDF]

, 2012
Antiplatelet therapy remains the mainstay in preventing aberrant platelet activation in pathophysiological conditions such as myocardial infarction, ischemia, and stroke.
Holinstat, Michael, Yeung, Jennifer
core   +3 more sources

Adjunctive Intravenous Argatroban or Eptifibatide for Ischemic Stroke. [PDF]

N Engl J Med
Intravenous thrombolysis is a standard treatment of acute ischemic stroke. The efficacy and safety of combining intravenous thrombolysis with argatroban (an anticoagulant agent) or eptifibatide (an antiplatelet agent) are unclear.We conducted a phase 3, three-group, adaptive, single-blind, randomized, controlled clinical trial at 57 sites in the United
Adeoye O, Broderick J, Derdeyn CP, Grotta JC, Barsan W, Bentho O, Berry S, Concha M, Davis I, Demel S, Elm J, Gentile N, Graves T, Hoffman M, Huang J, Ingles J, Janis S, Jasne AS, Khatri P, Levine SR, Majjhoo A, Panagos P, Pancioli A, Pizzella S, Ranasinghe T, Sabagha N, Sivakumar S, Streib C, Vagal A, Wilson A, Wintermark M, Yoo AJ, Barreto AD.   +32 more
europepmc   +3 more sources

Novel whole blood assay for phenotyping platelet reactivity in mice identifies ICAM-1 as a mediator of platelet-monocyte interaction [PDF]

, 2015
British Heart Foundation (PG/12/68/29779 and PG/14/48/30916) and the Wellcome Trust (101604/Z/13/Z to SN and TW, and 098291/Z/12/Z to S.N)
Abbott, Altieri, Alugupalli, Armstrong, Armstrong, Armstrong, Armstrong, Cattaneo, Cattaneo, Chan, Chan, Clark, di Minno, D’Souza, Fox, Freyer, Harrison, Hirsh, Huo, Iyú, Kevil, Kirkby, Konstantopoulos, Languino, Languino, Ley, Lordkipanidzé, McCaffery, Melissa V. Chan, Michaela Finsterbusch, Michelson, Nakamura, Nancy Hogg, Nicholas S. Kirkby, Patrono, Paul, Paul C. J Armstrong, Projahn, Rand, Shankar, Sussan Nourshargh, Threadgill, Timothy D. Warner, Turner, von Brühl, Warner, Woulfe, Xu   +47 more
core   +1 more source

A comprehensive evaluation of the activity and selectivity profile of ligands for RGD-binding integrins [PDF]

, 2017
Integrins, a diverse class of heterodimeric cell surface receptors, are key regulators of cell structure and behaviour, affecting cell morphology, proliferation, survival and differentiation.
Cavalcanti-Adam, Elisabetta Ada, Geiger, Benjamin, Kapp, Tobias G., Kessler, Horst, Maltsev, Oleg V., Mas Moruno, Carlos, Neubauer, Stefanie, Notni, Johannes, Rechenmacher, Florian, Reuning, Ute, Spatz, Joachim, Wester, Hans-Jürgen, Zarka, Revital   +12 more
core   +2 more sources

Eptifibatide in Coronary Intervention [PDF]

Circulation: Cardiovascular Interventions, 2015
Although percutaneous transluminal coronary intervention has revolutionized the management of patients with coronary artery disease, this technologic advance is neither innocuous nor a panacea. In addition to the technical limitations of the procedure, it is now well recognized that serious vascular injury is caused by the treatment device, which ...
Matthew W. Sherwood, James E. Tcheng
openaire   +3 more sources